Embark Biotech
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Embark Biotech, a 2017 spin-out from the University of Copenhagen's Novo Nordisk Foundation Center for Basic Metabolic Research, worked on novel targets regulating fat-tissue calorie burning and glucose and lipid uptake. Its lead programs were EMB1, a peptide for cardiometabolic disease, and EMB2, a small molecule designed to raise energy expenditure for obesity. In August 2023 Novo Nordisk acquired the company for 15 million euros upfront plus up to 456 million euros in milestones.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Embark Biotech spins out of the University of Copenhagen, founded by Zach Gerhart-Hines, Jakob Bondo Hansen and Thue Schwartz with seed support from Novo Holdings.
- Funding round
The company's last tracked funding round, a convertible note, closes in September 2021.
- Acquisition
Novo Nordisk acquires Embark Biotech on August 30, 2023 for 15 million euros upfront plus up to 456 million euros in milestones; the team continues as Embark Laboratories.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.